adMare
News
July 22 2024
Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW191, A Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
June 27 2024
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
June 17 2024
Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW171, A Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers
June 10 2024
Zymeworks Announces China NMPA Acceptance Of Biologics License Application For Zanidatamab For Second-Line Treatment Of Biliary Tract Cancer
June 06 2024
Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012
March 19 2024
Flosonics Medical Secures $20 Million USD in Series C Funding Led by New Leaf Venture Partners to Accelerate Growth
March 12 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy
March 04 2024
Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors
November 08 2023
Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions
October 10 2023
Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 405
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
